Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16881366 | 0.83 | KMT2A (0.44) | CA2P2RX7L3MBTL1ALDH1A1 | |
| SCHEMBL5968915 | 0.80 | P2RX7 (0.39) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22469063 | 0.78 | TSHR (0.39) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28116416 | 0.77 | CA2 (0.40) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25217366 | 0.76 | CYP1A2 (0.53) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL522658 | 0.76 | APOBEC3G (0.36) | TSHRLMNAGAAL3MBTL1HTT | |
| SCHEMBL3558621 | 0.76 | P2RX7 (0.51) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL26672084 | 0.75 | EPHX2 (0.43) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12234545 | 0.75 | RPS6KA1 (0.43) | CYP1A2CA2GAAL3MBTL1 | |
| SCHEMBL16396429 | 0.73 | P2RX7 (0.55) | P2RX7L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | CYP3A4, CYP2C9, AADAC | TSHR 2923/4885CYP1A2 17/4885CYP2D6 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.